Sanofi-Aventis Canada
Sanofi Canada is the Canadian subsidiary of Sanofi S.A. and the country's largest biopharma manufacturer, employing 2,000+ people across R&D, biomanufacturing, and an AI Centre of Excellence in Toronto to develop, produce, and distribute prescription medicines, vaccines, and patient support programs domestically and to 60+ countries.
- Company typePublic
- Founded1917
- HeadquartersParis, France
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sanofi-Aventis Canada does
Sanofi Canada is the Canadian subsidiary of Sanofi S.A., a France-based multinational pharmaceutical company, and operates as Canada's largest biopharma manufacturer and the only company investing, innovating, and operating across the full life sciences value chain domestically. Headquartered at the Toronto Campus in North York (1755 Steeles Ave W), the largest biotech site in Canada, the company employs 2,000+ people focused on delivering first- and best-in-class medicines and vaccines. The Canadian entity has over 100 years of operating history, with roots dating back to 1917 when the Toronto Campus was originally called 'Laboratory.'
Sanofi's Canadian business is built around an integrated portfolio of prescription products and medical devices, vaccines and immunoprophylaxis products, and patient support programs. Key products include Rezurock (belumosudil tablets) for chronic graft-versus-host disease in patients aged 12+ after failure of at least two prior systemic therapies, and Fluzone High-Dose, an influenza vaccine demonstrating superior protection in adults aged 65+ per the FLUNITY-HD study. The company protects over 7 million Canadians annually against infectious diseases and exports vaccines to over 60 countries. Underlying capabilities include world-leading R&D and biomanufacturing facilities in Toronto, plus a dedicated AI Centre of Excellence at 240 Richmond St W that develops data and AI products to accelerate research and development.
The business model is sales-led and enterprise-focused, monetizing through one-time prescription product sales and vaccine hardware sales distributed via provincial public reimbursement programs, direct healthcare provider channels (hospitals, clinics, pharmacies), and international export partnerships. Customers span government health systems (e.g., Government of Quebec for Rezurock reimbursement), healthcare providers, and end patients reached through public health and vaccination programs. Pricing is managed through public reimbursement negotiations, government health technology assessments (e.g., Canada Drug Agency, INESSS), and standard pharmaceutical pricing models rather than disclosed consumer-facing pricing.
Sanofi-Aventis Canada firmographics
Firmographics- Name
- Sanofi-Aventis Canada
- Legal name
- Sanofi Canada
- Website
- https://sanofi.ca
- Company type
- Public
- Founded year
- 1917
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sanofi Canada is the Canadian subsidiary of Sanofi S.A. and the country's largest biopharma manufacturer, employing 2,000+ people across R&D, biomanufacturing, and an AI Centre of Excellence in Toronto to develop, produce, and distribute prescription medicines, vaccines, and patient support programs domestically and to 60+ countries.
- Ownership category
- akta.pro rank
Sanofi-Aventis Canada industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Sanofi-Aventis Canada is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Sanofi-Aventis Canada business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Products: Revenue generated from prescription medicines and vaccines sold to healthcare providers, hospitals, and government health programs through public reimbursement and private sales
- Vaccines: Vaccine products protecting against infectious diseases, distributed domestically to Canadians and exported internationally to over 60 countries
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Sanofi-Aventis Canada product offering
Product offeringCore offering
Sanofi Canada is Canada's largest biopharma manufacturer and the only company investing, innovating, and operating across the full life sciences value chain. It researches, develops, manufactures, and distributes prescription medicines (e.g., Rezurock for chronic graft-versus-host disease) and vaccines (e.g., Fluzone High-Dose for adults 65+), supported by patient support programs. Operations are anchored at the Toronto Campus (R&D and biomanufacturing) and an AI Centre of Excellence in Toronto.
Product overview
Sanofi Canada operates as Canada's largest biopharma manufacturer and the only company investing, innovating and operating across the full life sciences value chain. The company's portfolio consists of prescription products and medical devices (including Rezurock® for chronic GVHD), vaccines and immunoprophylaxis products (including Fluzone High-Dose influenza vaccine), and patient support programs. The company maintains world-leading R&D and biomanufacturing facilities in Toronto, along with an AI Centre of Excellence focused on developing data and AI products to accelerate research and development.
Differentiator
Problem solved
Functional benefit
Products and services
- Rezurock (belumosudil tablets) Prescription medicine (belumosudil tablets) for treating adults and children aged 12 and older with chronic graft-versus-host disease after failure of at least two prior systemic therapies. Sold to hospitals, clinics, and pharmacies; reimbursed via provincial drug plans.
- Fluzone High-Dose Influenza Vaccine
Quantifiable outcome
- Significant reduction in hospitalizations among adults 65+ against laboratory-confirmed influenza, pneumonia, cardio-respiratory hospitalizations, and all-cause hospitalizations compared to standard-dose vaccines
Companies that use Sanofi-Aventis Canada
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Sanofi-Aventis Canada technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature1 record
Sanofi-Aventis Canada partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights5 records
Sanofi-Aventis Canada competitors and assessment
Company assessmentDirect peers
- AbbVie Canada: AbbVie Canada is a major specialty biologic and immunology pharmaceutical manufacturer in Canada, directly competing with Sanofi in immunology indications (e.g., chronic GVHD overlap with Humira/Skyrizi franchises) for Canadian reimbursement and prescriber share.
- AstraZeneca Canada: AstraZeneca Canada markets a comparable portfolio of prescription pharmaceuticals and biologics in Canada, including respiratory and oncology products that overlap with Sanofi's therapeutic areas, and competes directly for reimbursement and physician adoption.
- Eli Lilly Canada: Eli Lilly Canada is the Canadian subsidiary of Eli Lilly, a major pharmaceutical manufacturer with comparable biologics, vaccines (e.g., COVID), and chronic-disease franchises that compete directly in Canadian reimbursement and prescriber markets.
- Pfizer Canada: Pfizer Canada is the Canadian subsidiary of Pfizer Inc., a global pharmaceutical manufacturer with comparable prescription medicines, vaccines (including mRNA COVID vaccines), and biomanufacturing operations. Both compete for the same Canadian healthcare providers, public reimbursement listings, and vaccine market share.
- GSK Canada: GSK Canada is a major vaccines and specialty pharmaceuticals competitor with overlapping influenza and adult vaccine portfolios. Both companies compete directly in Canadian public health immunization programs and respiratory vaccine categories.
- Novartis Pharmaceuticals Canada: Novartis Pharmaceuticals Canada operates a comparable prescription pharmaceutical business in Canada, including biologics, specialty medicines, and clinical research. It competes for the same healthcare-provider prescribing and provincial reimbursement listings.
- Merck Canada (MSD): Merck Canada, the Canadian arm of MSD, operates a comparable pharmaceutical business spanning vaccines (e.g., Gardasil), biologics, and specialty prescription medicines, and directly competes for Canadian reimbursement listings and healthcare-provider share-of-voice.
- Roche Canada: Roche Canada is the Canadian subsidiary of Roche, a global pharmaceutical and diagnostics company. It competes in specialty biologics and personalized therapeutics, sharing the same Canadian reimbursement and prescriber channels as Sanofi.
- Johnson & Johnson Innovative Medicine Canada: J&J Innovative Medicine Canada is the Canadian pharmaceutical arm of Johnson & Johnson, with comparable biologic and specialty pharmaceutical offerings across immunology and oncology that compete with Sanofi in Canadian reimbursement listings.
- Bristol-Myers Squibb Canada: BMS Canada operates a comparable specialty pharmaceutical business in oncology, immunology, and cardiovascular therapy. It directly competes with Sanofi for the same healthcare provider, hospital, and public reimbursement channels in Canada.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Sanofi-Aventis Canada social profiles
Digital presenceSanofi-Aventis Canada financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanofi-Aventis Canada leadership team
Management profileNumber of profiles
Sanofi-Aventis Canada funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanofi-Aventis Canada M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanofi-Aventis Canada
What does Sanofi-Aventis Canada do?
Sanofi Canada is Canada's largest biopharma manufacturer and the only company investing, innovating, and operating across the full life sciences value chain. It researches, develops, manufactures, and distributes prescription medicines (e.g., Rezurock for chronic graft-versus-host disease) and vaccines (e.g., Fluzone High-Dose for adults 65+), supported by patient support programs. Operations are anchored at the Toronto Campus (R&D and biomanufacturing) and an AI Centre of Excellence in Toronto.
Is Sanofi-Aventis Canada a public or private company?
Sanofi-Aventis Canada is a public company. It is classified as corporate owned and is currently operating.
When was Sanofi-Aventis Canada founded?
Sanofi-Aventis Canada was founded in 1917. It employs 5,001 to 10,000 people.
Where is Sanofi-Aventis Canada based?
Sanofi-Aventis Canada is headquartered in Paris, France, in the Europe region.
How does Sanofi-Aventis Canada make money?
Two revenue lines are on record. Pharmaceutical Products are the primary driver. The others are vaccines.
Who are Sanofi-Aventis Canada's main competitors?
Direct peers on record are AbbVie Canada, AstraZeneca Canada, Eli Lilly Canada, Pfizer Canada, GSK Canada, Novartis Pharmaceuticals Canada, Merck Canada (MSD), Roche Canada, Johnson & Johnson Innovative Medicine Canada and Bristol-Myers Squibb Canada.
Does Sanofi-Aventis Canada have an API?
No public API is recorded for Sanofi-Aventis Canada.
What industry is Sanofi-Aventis Canada in?
Sanofi-Aventis Canada's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIAEAK, Vaccine Cold Chain, Storage & Distribution. Its NAICS code is 325412 and its SIC code is 2834.